Related Experiment Videos
Antifungal agents. Part I. Amphotericin B preparations and flucytosine
1Division of Infectious Diseases and Internal Medicine, Mayo Clinic Rochester, Minnesota, USA.
Abstract:
Traditionally, amphotericin B has been the cornerstone of antifungal treatment. Toxicity, however, is a major dose-limiting factor of amphotericin B deoxycholate. Nevertheless, it continues to have a major role in the treatment of deep-seated mycotic infections. Recently, less nephrotic lipid formulations, including amphotericin B lipid complex, amphotericin B cholesteryl sulfate, and liposomal amphotericin B, have been introduced. The pharmacologic properties, main indications, recommended dosages, related costs, and adverse effects of these various preparations are summarized in this review. Orally administered flucytosine is useful in certain infections, particularly cryptococcal meningitis, but it should be used with caution in patients with renal insufficiency.
Insights
Amphotericin B is a key antifungal, but its toxicity limits use. Newer lipid formulations offer reduced kidney damage for treating deep fungal infections, with flucytosine useful for specific cases like cryptococcal meningitis.
Area of Science:
- Mycology
- Pharmacology
- Infectious Diseases
Background:
- Amphotericin B deoxycholate is a traditional antifungal but causes significant toxicity, limiting its use.
- Deep-seated mycotic infections require effective treatment, historically relying on amphotericin B.
- Emerging lipid formulations of amphotericin B aim to mitigate toxicity, particularly nephrotoxicity.
Purpose of the Study:
- To review the pharmacologic properties of various amphotericin B formulations.
- To summarize indications, dosages, costs, and adverse effects of amphotericin B preparations.
- To discuss the role of flucytosine in specific fungal infections.
Main Methods:
- Literature review of amphotericin B and flucytosine.
- Comparative analysis of different amphotericin B formulations.
- Summary of clinical guidelines and pharmacoeconomic data.
Main Results:
- Lipid formulations (lipid complex, cholesteryl sulfate, liposomal) show reduced nephrotoxicity compared to deoxycholate.
- Each formulation has distinct pharmacologic profiles, indications, and cost implications.
- Flucytosine is effective for certain infections like cryptococcal meningitis but requires renal function monitoring.
Conclusions:
- Lipid formulations of amphotericin B represent a safer alternative for treating invasive fungal infections.
- Careful consideration of formulation, indication, and patient factors is crucial for optimal antifungal therapy.
- Flucytosine remains a valuable adjunct, especially in CNS fungal infections, with appropriate precautions.